Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 1, 2026, 5:04 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 85 matching trials from the live ClinicalTrials.gov search.
Conditions
Myelodysplastic Syndrome (MDS), Chronic Lymphocytic Leukemia (CLL), Chemotherapy-sensitive Lymphoma, Acute Lymphoblastic Leukemia (ALL)/T Lymphoblastic Lymphoma, Acute Myelogenous Leukemia (AML), Acute Biphenotypic Leukemia (ABL), Acute Undifferentiated Leukemia (AUL)
Interventions
Fludarabine, Cyclophosphamide 14.5 mg/kg/day IV on Days -6, -5, Total Body Irradiation (TBI) 200cGy on Day -1, Infusion of non-T-cell depleted bone marrow on Day 0, Busulfan, Cyclophosphamide 50mg/kg/day IV on Days -2,-1, Cyclophosphamide 50mg/kg/day IV on Days -5,-4, Total Body Irradiation (TBI) 200cGy twice a day on Days -3, -2, -1, Post-HCT Cyclophosphamide 50mg/kg IV on Day+3, +4, Sirolimus, Mycophenolate mofetil, G-CSF, Pre-HCT Mesna on Days -6 and -5, Pre-HCT Mesna on Days -2 and -1, Pre-HCT Mesna on Days -5 and -4, Post-HCT Mesna
Drug · Radiation · Procedure
Lead sponsor
Center for International Blood and Marrow Transplant Research
Network
Eligibility
15 Years to 70 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
11
States / cities
Gainesville, Florida • Miami, Florida • Tampa, Florida + 7 more
Conditions
Acute Leukemia, Immune Deficiency Disorder, Congenital Hematological Disorder, Metabolism Disorder, Aplastic Anemia, Myelodysplastic Syndromes, Chronic Leukemia, Lymphoma, Multiple Myeloma, Solid Tumor
Interventions
Total Body Irradiation 1200 cGy, Total Body Irradiation 200 cGy, Cyclophosphamide, Mesna, Cord Blood Infusion, Busulfan, Fludarabine, Melphalan
Radiation · Drug · Procedure
Lead sponsor
University of Rochester
Other
Eligibility
2 Months to 75 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2027
U.S. locations
1
States / cities
Rochester, New York
Completed Phase 2Phase 3 Interventional Results available

Stem Cell Transplant (SCT) for Dyskeratosis Congenita or SAA

NCT00455312
Conditions
Dyskeratosis Congenita, Aplastic Anemia
Interventions
Campath 1H, Cyclophosphamide, Fludarabine, Total Body Irradiation, Stem Cell Transplantation, antithymocyte globulin, Methylprednisolone
Drug · Procedure
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Up to 70 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2016
U.S. locations
1
States / cities
Minneapolis, Minnesota
Conditions
Graft Versus Host Disease, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Secondary Myelofibrosis
Interventions
cyclophosphamide, cyclosporine, fludarabine phosphate, mycophenolate mofetil, Treg cell infusion, umbilical cord blood transplantation, total-body irradiation
Drug · Procedure · Radiation
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years to 45 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Minneapolis, Minnesota
Terminated Phase 1Phase 2 Interventional Results available

Stem Cell Transplantation for Fanconi Anemia

NCT00167206
Conditions
Fanconi Anemia
Interventions
Hematopoietic Stem Cell Transplant, Thymic Shielding During Radiation, Total Body Irradiation, Cyclophosphamide, Fludarabine
Procedure · Drug
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
1 Day to 18 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Minneapolis, Minnesota
Conditions
Lymphoma, Non-Hodgkin
Interventions
Cyclophosphamide, BCNU, Etoposide, Filgrastim, Antithymocyte globulin, Cyclosporine, Mycophenolate mofetil, Rituximab, Autologous hematopoietic stem cell transplantation (auto-HSCT), Allogeneic hematopoietic stem cell transplantation (allo-HSCT), Total lymphoid irradiation, CD34+ Cells, Solu-Medrol
Drug · Procedure
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 70 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2017
U.S. locations
1
States / cities
Stanford, California
Conditions
Withdrawal Symptoms, Opioid Use Disorder, Opioid Use
Interventions
Transcutaneous Cervical Vagal Nerve Stimulation, Sham Stimulation, [F-18]Fallypride
Device · Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 75 Years
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
6
States / cities
Atlanta, Georgia
Conditions
Acute Myelogenous Leukemia, Acute Lymphatic Leukemia, Chronic Myelogenous Leukemia, Myelodysplastic Syndromes, Myelodysplastic Syndrome Other, Chronic Myelomonocytic Leukemia, Lymphoma, Hodgkin Lymphoma
Interventions
Cyclophosphamide, Fludarabine, Thiotepa, Total Body Irradiation, Double Umbilical Cord Transplant, Tacrolimus, Mycophenolate Mofetil, Abatacept
Drug · Radiation · Biological
Lead sponsor
Leland Metheny
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Cleveland, Ohio
Conditions
Melanoma
Interventions
Physical Examination, Solar Simulated Light
Procedure · Other
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years to 100 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Portland, Oregon
Conditions
Head and Neck Cancer
Interventions
Radiotherapy, Leucovorin, Cetuximab, Filgrastim, Erythropoetin, Cisplatin, Fluorouracil, Docetaxel
Radiation · Drug · Biological
Lead sponsor
Drexel University College of Medicine
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Metastatic Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Cancer
Interventions
Stereotactic Body Radiation Therapy, Botensilimab, Balstilimab
Radiation · Drug
Lead sponsor
Benjamin Spieler
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Miami, Florida
Conditions
Related Donors Donating Peripheral Blood Stem Cells (PBSC) to a Family Member, Acute Myelogenous Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, Chronic Myelogenous Leukemia, Non-Hodgkin's Lymphoma, Hodgkin's Disease, Chronic Lymphocytic Leukemia
Interventions
Plerixafor
Drug
Lead sponsor
Center for International Blood and Marrow Transplant Research
Network
Eligibility
18 Years to 65 Years
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
12
States / cities
Tampa, Florida • Atlanta, Georgia • Chicago, Illinois + 9 more
Conditions
Multiple Myeloma
Interventions
One Autologous Transplant, Non-Myeloablative Allogeneic Transplant, Second Autologous Transplant, Thalidomide, Dexamethasone, Observation
Procedure · Drug · Behavioral
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
Up to 70 Years
Enrollment
710 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2013
U.S. locations
36
States / cities
Birmingham, Alabama • Phoenix, Arizona • Duarte, California + 28 more
Conditions
Hematologic Malignancies, Acute Leukemia, Myelodysplastic Syndromes (MDS) Other Than RA or RARS Subtypes, Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma, Myeloma, Chronic Myelogenous (or Myeloid) Leukemia (CML) Resistant to STI Therapy
Interventions
Fludarabine, Thiotepa, Total Body Irradiation (TBI), Donor Lymphocyte Infusion (DLI), Melphalan, Hematopoietic stem cell transplantation (HSCT)
Drug · Radiation · Biological + 1 more
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Osteosarcoma, Pulmonary Recurrence of Osteosarcoma
Interventions
Surgical Resection, Stereotactic Body Radiation Therapy (SBRT), Atezolizumab
Procedure · Radiation · Drug
Lead sponsor
Emory University
Other
Eligibility
Up to 50 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Atlanta, Georgia
Conditions
Liver Cancer, Intrahepatic Cholangiocarcinoma, Liver Metastases, HCC
Interventions
MRI-guided adaptive stereotactic ablative body radiotherapy (SABR)
Radiation
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Palo Alto, California
Conditions
Sickle Cell Disease
Interventions
Cyclophosphamide, Fludarabine, Mycophenolate mofetil, Sirolimus, Allogeneic bone marrow transplant, Total body irradiation - 200, Levetiracetam, Anti-thymocyte globulin, Total body irradiation - 400
Drug · Procedure · Radiation + 1 more
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
2 Years to 70 Years
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2018
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Sickle Cell Disease
Interventions
Busulfan, Fludarabine, r-ATG, Hematopoietic Cell Transplant, Tacrolimus, Methotrexate, Standard of Care, Alemtuzumab, Total Body Irradiation (TBI), Sirolimus, Melphalan, G-CSF
Drug · Procedure
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
15 Years to 40 Years
Enrollment
138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
35
States / cities
Oakland, California • Washington D.C., District of Columbia • Gainesville, Florida + 25 more
Conditions
Prostate Cancer
Interventions
1.5 T Elekta Unity MR-Linac system, Hydrogel rectal spacer (SpaceOAR)
Radiation · Device
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older · Male only
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
New York, New York
Conditions
Acute Myeloid Leukemia, Myelodysplastic Syndrome, Acute Lymphocytic Leukemia
Interventions
Fludarabine, Fractionated total body irradiation, Busulfan, Cyclophosphamide, Single dose total body irradiation, Melphalan, Granulocyte-colony stimulating factor, Stem cell transplant, Azacitidine
Drug · Radiation · Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
St Louis, Missouri
Conditions
Peripheral Blood Stem Cell Transplantation, Hematopoietic Stem Cell Transplantation
Interventions
Melphalan, Sirolimus, Total Body Irradiation (TBI), Cyclophosphamide, Mycophenolate Mofeti, Fludarabine, Allogeneic HSCT, Mesna, Filgrastim
Drug · Radiation · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
12 Years to 120 Years
Enrollment
260 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2028
U.S. locations
2
States / cities
Duarte, California • Bethesda, Maryland
Conditions
Uveal Melanoma
Interventions
stereotactic body radiotherapy, Immunotherapy
Radiation · Drug
Lead sponsor
California Pacific Medical Center Research Institute
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
San Francisco, California
Completed Phase 2 Interventional Results available

Off-the-shelf NK Cells + SCT for Myeloid Malignancies

NCT05115630
Conditions
Myeloid Malignancies, Acute Myeloid Leukemia, Myelodysplastic Syndrome, Chronic Myeloid Leukemia
Interventions
Cyclophosphamide, Mesna, Filgrastim, Melphalan, Fludarabine phosphate, Tacrolimus, Mycophenolate mofetil, Total Body Irradiation One Dose
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 70 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Houston, Texas
Conditions
Lymphoma
Interventions
carmustine, cyclophosphamide, etoposide, peripheral blood stem cell transplantation, irradiation therapy, G-CSF, Cytarabine
Drug · Procedure · Radiation + 1 more
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Up to 75 Years
Enrollment
473 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2019
U.S. locations
1
States / cities
Minneapolis, Minnesota